Advertisement

Topics

KOL Perspectives: Perception of mirikizumab in moderatetosevere UC [Report Updated: 28082018] Prices from USD $2500

08:37 EST 10 Jan 2019 | BioPortfolio Reports

KOL Perspectives: Perception of mirikizumab in moderatetosevere UC


Summary


This KOL Insight briefing focuses on KOLs views of mirikizumab in moderatetosevere UC.


Questions topics

Perception of Phase II mirikizumab induction data in UC

Perception of mirikizumab's Phase III study in UC

Future expectations of mirikizumab in UC

Future expectations for mirikizumab in Crohn's disease


Key Highlights


All but one KOL noted that 200mg was the optimal dose for mirikizumab in UC, while flagging the lack of dose response

Endoscopic histological healing highlighted by most KOLs as suitable secondary endpoints in mirikizumab's ongoing Phase III UC trial

KOLs could not differentiate the clinical profile of mirikizumab in UC from other antiIL23s, and were divided over its dosing regimen.


Scope


The insight briefing is based on Sociable Pharma's analysis of primary research with our ulcerative colitis key opinion leaders KOLs.


In total, we conducted interviews with 10 KOLs

5 Europebased 5 N. Americabased

Interviews performed during July 2018


KOL data is analyzed to produce

Charts summarizing KOL opinions

Chart callouts of key information details

KOL quotes

Summary of KOL reporting trends

Insight from Sociable Pharma's analysts


Reasons to buy


Combines Qualitative semiquantitative insight from key opinion leaders on mirikizumab in moderatetosevere UC

Includes insight recommendations from our diseasespecific healthcare analysts

Utilizes independent expert viewpoints to validate the impact of new clinical data emerging trends on management of UC

Provides costeffective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Original Article: KOL Perspectives: Perception of mirikizumab in moderatetosevere UC [Report Updated: 28082018] Prices from USD $2500

NEXT ARTICLE

More From BioPortfolio on "KOL Perspectives: Perception of mirikizumab in moderatetosevere UC [Report Updated: 28082018] Prices from USD $2500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Crohn's Disease (CD)
Crohn’s disease (CD) is a long-term condition that causes inflammation of the lining of the digestive system.  Inflammation can affect any part of the digestive system, from the mouth to the back passage, but most commonly occurs in the last s...

Complementary and Alternative Medicine
Alternative medicine are whole medical systems that did not fit with conventional medicine as they have completely different philosophies and ideas on the causes of disease, methods of diagnosis and approaches to treatment. Although often overlapping, co...